Global Long Acting Drug Delivery Market
Global Long Acting Drug Delivery Market

Long Acting Drug Delivery Comprehensive Study by Injectable (Sterile Liquid and Powder Filling, Lyophilization, Homogenization, Spray Drying), End-Use Industries (Pharmaceuticals, Clinical, Medical Centre, Others), Implants (Extensive Statistical-based Modelling, Hot Melt Extrusion (HME), Co-extrusion, Injection Molding, Cryo-milling and Jet Milling, Surface Dip and Spray Coating, High-shear Mixing) Players and Region - Global Market Outlook to 2026

Long Acting Drug Delivery Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 241 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Long Acting Drug Delivery Market Overview:
A long-acting system is a combination of products and implantable systems. It is a system such as implants, depot injections, and combination products.

Growth Drivers
  • Growing cases of chronic diseases
  • An increasingly popular approach for sustained drug delivery, offering the potential for targeted drug release, lower dosage requirements, and improved patient compliance
  • The high growth of this segment is attributed to the rising demand for biologics

Roadblocks
  • High cost of the product
  • Lack of medication compliance which detrimental to treatment response

Opportunities
  • Technological advancement in new product launches
  • Development of long-acting drug delivery platform to treat chronic disorders
  • Rapidly developing bespoke ex vivo disease models to test the implant performance
  • Rapid technological advancements in the field of injectable drug delivery that create new opportunities

Challenges
  • An increasing number of diseases such as cancer


Competitive Landscape:
Companies in the market are concentrating on pharmaceutical and drug delivery. The new product launch and high growth in the healthcare market are expected to offer significant growth opportunities for the market during the forecast period. North America, the fastest-growing country in the region due to the increased R&D investments, rise in healthcare expenditure, and government initiatives to support the development of advanced diagnostic procedures.
Some of the key players profiled in the report are National Center for Biotechnology Information (United States), Lubrizol Life Science Health - CDMO Division (United States), West Pharmaceutical Services (United States), Celanese (United States), DelsiTech Oy (Finland), Gerresheimer AG (Germany), Baxter International, Inc. (United States), Pfizer, Inc. (United States), Alkermes Plc. (Irland), Becton Dickinson and Company (United States), Eli Lilly and Company (United States), Schott AG (Germany), Terumo Corporation (Japan), Unilife Corporation (United States), Endocyte (United States) and Genentech Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Elcam Medical (Italy) and Teva Pharmaceuticals Industries Ltd. (Israel). Analyst at AMA Research see United States Players to retain maximum share of Global Long Acting Drug Delivery market by 2026. Considering Market by Injectable, the sub-segment i.e. Sterile Liquid and Powder Filling will boost the Long Acting Drug Delivery market. Considering Market by End-Use Industries , the sub-segment i.e. Pharmaceuticals will boost the Long Acting Drug Delivery market. Considering Market by Implants, the sub-segment i.e. Extensive Statistical-based Modelling will boost the Long Acting Drug Delivery market.

6 Nov, 2017: West Pharmaceutical Services, Inc. presented a new extension of SMARTDOSE drug delivery platform. This platform includes wearable injectors and it allows for up to 10 mL of volume to be injected in easy-to-use, wearable formats. and 19 Oct, 2021: West Pharmaceutical Services, Inc. introduced the DeltaCube Modeling Platform as well as the new NovaGuard SA Pro Safety System. This system is designed to help developers to make more confident decisions about their container closure systems.

What Can be Explored with the Long Acting Drug Delivery Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Long Acting Drug Delivery Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Long Acting Drug Delivery
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Long Acting Drug Delivery market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Long Acting Drug Delivery market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Healthcare Industry/Centres, Research & Development, Medical Centres, Manufacturers, Pharmaceutical Scientists, Biomedical Engineers and Clinicians.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Long Acting Drug Delivery Market?
The Long Acting Drug Delivery market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Long Acting Drug Delivery Market?
Top performing companies in the Global Long Acting Drug Delivery market are National Center for Biotechnology Information (United States), Lubrizol Life Science Health - CDMO Division (United States), West Pharmaceutical Services (United States), Celanese (United States), DelsiTech Oy (Finland), Gerresheimer AG (Germany), Baxter International, Inc. (United States), Pfizer, Inc. (United States), Alkermes Plc. (Irland), Becton Dickinson and Company (United States), Eli Lilly and Company (United States), Schott AG (Germany), Terumo Corporation (Japan), Unilife Corporation (United States), Endocyte (United States) and Genentech Inc. (United States), to name a few.

3. What trending factors would impact Long Acting Drug Delivery Market growth most?
"Innovation in drug delivery to improve patient compliance " is seen as one of major influencing trends for Long Acting Drug Delivery Market during projected period 2020-2026.

Report Objectives / Segmentation Covered
By Injectable
  • Sterile Liquid and Powder Filling
  • Lyophilization
  • Homogenization
  • Spray Drying

By End-Use Industries
  • Pharmaceuticals
  • Clinical
  • Medical Centre
  • Others

By Implants
  • Extensive Statistical-based Modelling
  • Hot Melt Extrusion (HME)
  • Co-extrusion
  • Injection Molding
  • Cryo-milling and Jet Milling
  • Surface Dip and Spray Coating
  • High-shear Mixing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing cases of chronic diseases
      • 3.2.2. An increasingly popular approach for sustained drug delivery, offering the potential for targeted drug release, lower dosage requirements, and improved patient compliance
      • 3.2.3. The high growth of this segment is attributed to the rising demand for biologics
    • 3.3. Market Challenges
      • 3.3.1. An increasing number of diseases such as cancer
    • 3.4. Market Trends
      • 3.4.1. Innovation in drug delivery to improve patient compliance
      • 3.4.2. A growing trend in wearable injector devices, which are being developed to provide convenient, at-home administration of biologics
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Long Acting Drug Delivery, by Injectable, End-Use Industries , Implants and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Long Acting Drug Delivery (Value)
      • 5.2.1. Global Long Acting Drug Delivery by: Injectable (Value)
        • 5.2.1.1. Sterile Liquid and Powder Filling
        • 5.2.1.2. Lyophilization
        • 5.2.1.3. Homogenization
        • 5.2.1.4. Spray Drying
      • 5.2.2. Global Long Acting Drug Delivery by: Implants (Value)
        • 5.2.2.1. Extensive Statistical-based Modelling
        • 5.2.2.2. Hot Melt Extrusion (HME)
        • 5.2.2.3. Co-extrusion
        • 5.2.2.4. Injection Molding
        • 5.2.2.5. Cryo-milling and Jet Milling
        • 5.2.2.6. Surface Dip and Spray Coating
        • 5.2.2.7. High-shear Mixing
      • 5.2.3. Global Long Acting Drug Delivery Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Long Acting Drug Delivery (Price)
  • 6. Long Acting Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. National Center for Biotechnology Information (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lubrizol Life Science Health - CDMO Division (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. West Pharmaceutical Services (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celanese (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. DelsiTech Oy (Finland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Gerresheimer AG (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Baxter International, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alkermes Plc. (Irland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Becton Dickinson and Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eli Lilly and Company (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Schott AG (Germany)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Terumo Corporation (Japan)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Unilife Corporation (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Endocyte (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Genentech Inc. (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Long Acting Drug Delivery Sale, by Injectable, End-Use Industries , Implants and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Long Acting Drug Delivery (Value)
      • 7.2.1. Global Long Acting Drug Delivery by: Injectable (Value)
        • 7.2.1.1. Sterile Liquid and Powder Filling
        • 7.2.1.2. Lyophilization
        • 7.2.1.3. Homogenization
        • 7.2.1.4. Spray Drying
      • 7.2.2. Global Long Acting Drug Delivery by: Implants (Value)
        • 7.2.2.1. Extensive Statistical-based Modelling
        • 7.2.2.2. Hot Melt Extrusion (HME)
        • 7.2.2.3. Co-extrusion
        • 7.2.2.4. Injection Molding
        • 7.2.2.5. Cryo-milling and Jet Milling
        • 7.2.2.6. Surface Dip and Spray Coating
        • 7.2.2.7. High-shear Mixing
      • 7.2.3. Global Long Acting Drug Delivery Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Long Acting Drug Delivery (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Long Acting Drug Delivery: by Injectable(USD Million)
  • Table 2. Long Acting Drug Delivery Sterile Liquid and Powder Filling , by Region USD Million (2015-2020)
  • Table 3. Long Acting Drug Delivery Lyophilization , by Region USD Million (2015-2020)
  • Table 4. Long Acting Drug Delivery Homogenization , by Region USD Million (2015-2020)
  • Table 5. Long Acting Drug Delivery Spray Drying , by Region USD Million (2015-2020)
  • Table 6. Long Acting Drug Delivery: by Implants(USD Million)
  • Table 7. Long Acting Drug Delivery Extensive Statistical-based Modelling , by Region USD Million (2015-2020)
  • Table 8. Long Acting Drug Delivery Hot Melt Extrusion (HME) , by Region USD Million (2015-2020)
  • Table 9. Long Acting Drug Delivery Co-extrusion , by Region USD Million (2015-2020)
  • Table 10. Long Acting Drug Delivery Injection Molding , by Region USD Million (2015-2020)
  • Table 11. Long Acting Drug Delivery Cryo-milling and Jet Milling , by Region USD Million (2015-2020)
  • Table 12. Long Acting Drug Delivery Surface Dip and Spray Coating , by Region USD Million (2015-2020)
  • Table 13. Long Acting Drug Delivery High-shear Mixing , by Region USD Million (2015-2020)
  • Table 14. South America Long Acting Drug Delivery, by Country USD Million (2015-2020)
  • Table 15. South America Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 16. South America Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 17. South America Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 18. Brazil Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 19. Brazil Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 20. Brazil Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 21. Argentina Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 22. Argentina Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 23. Argentina Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 24. Rest of South America Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 25. Rest of South America Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 26. Rest of South America Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 27. Asia Pacific Long Acting Drug Delivery, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 29. Asia Pacific Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 30. Asia Pacific Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 31. China Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 32. China Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 33. China Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 34. Japan Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 35. Japan Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 36. Japan Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 37. India Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 38. India Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 39. India Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 40. South Korea Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 41. South Korea Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 42. South Korea Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 43. Taiwan Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 44. Taiwan Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 45. Taiwan Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 46. Australia Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 47. Australia Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 48. Australia Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 52. Europe Long Acting Drug Delivery, by Country USD Million (2015-2020)
  • Table 53. Europe Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 54. Europe Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 55. Europe Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 56. Germany Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 57. Germany Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 58. Germany Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 59. France Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 60. France Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 61. France Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 62. Italy Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 63. Italy Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 64. Italy Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 65. United Kingdom Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 66. United Kingdom Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 67. United Kingdom Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 68. Netherlands Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 69. Netherlands Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 70. Netherlands Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 71. Rest of Europe Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 72. Rest of Europe Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 73. Rest of Europe Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 74. MEA Long Acting Drug Delivery, by Country USD Million (2015-2020)
  • Table 75. MEA Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 76. MEA Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 77. MEA Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 78. Middle East Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 79. Middle East Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 80. Middle East Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 81. Africa Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 82. Africa Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 83. Africa Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 84. North America Long Acting Drug Delivery, by Country USD Million (2015-2020)
  • Table 85. North America Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 86. North America Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 87. North America Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 88. United States Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 89. United States Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 90. United States Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 91. Canada Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 92. Canada Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 93. Canada Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 94. Mexico Long Acting Drug Delivery, by Injectable USD Million (2015-2020)
  • Table 95. Mexico Long Acting Drug Delivery, by End-Use Industries USD Million (2015-2020)
  • Table 96. Mexico Long Acting Drug Delivery, by Implants USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Long Acting Drug Delivery: by Injectable(USD Million)
  • Table 114. Long Acting Drug Delivery Sterile Liquid and Powder Filling , by Region USD Million (2021-2026)
  • Table 115. Long Acting Drug Delivery Lyophilization , by Region USD Million (2021-2026)
  • Table 116. Long Acting Drug Delivery Homogenization , by Region USD Million (2021-2026)
  • Table 117. Long Acting Drug Delivery Spray Drying , by Region USD Million (2021-2026)
  • Table 118. Long Acting Drug Delivery: by Implants(USD Million)
  • Table 119. Long Acting Drug Delivery Extensive Statistical-based Modelling , by Region USD Million (2021-2026)
  • Table 120. Long Acting Drug Delivery Hot Melt Extrusion (HME) , by Region USD Million (2021-2026)
  • Table 121. Long Acting Drug Delivery Co-extrusion , by Region USD Million (2021-2026)
  • Table 122. Long Acting Drug Delivery Injection Molding , by Region USD Million (2021-2026)
  • Table 123. Long Acting Drug Delivery Cryo-milling and Jet Milling , by Region USD Million (2021-2026)
  • Table 124. Long Acting Drug Delivery Surface Dip and Spray Coating , by Region USD Million (2021-2026)
  • Table 125. Long Acting Drug Delivery High-shear Mixing , by Region USD Million (2021-2026)
  • Table 126. South America Long Acting Drug Delivery, by Country USD Million (2021-2026)
  • Table 127. South America Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 128. South America Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 129. South America Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 130. Brazil Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 131. Brazil Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 132. Brazil Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 133. Argentina Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 134. Argentina Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 135. Argentina Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 136. Rest of South America Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 137. Rest of South America Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 138. Rest of South America Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 139. Asia Pacific Long Acting Drug Delivery, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 141. Asia Pacific Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 142. Asia Pacific Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 143. China Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 144. China Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 145. China Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 146. Japan Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 147. Japan Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 148. Japan Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 149. India Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 150. India Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 151. India Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 152. South Korea Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 153. South Korea Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 154. South Korea Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 155. Taiwan Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 156. Taiwan Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 157. Taiwan Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 158. Australia Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 159. Australia Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 160. Australia Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 164. Europe Long Acting Drug Delivery, by Country USD Million (2021-2026)
  • Table 165. Europe Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 166. Europe Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 167. Europe Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 168. Germany Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 169. Germany Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 170. Germany Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 171. France Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 172. France Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 173. France Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 174. Italy Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 175. Italy Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 176. Italy Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 177. United Kingdom Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 178. United Kingdom Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 179. United Kingdom Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 180. Netherlands Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 181. Netherlands Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 182. Netherlands Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 183. Rest of Europe Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 184. Rest of Europe Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 185. Rest of Europe Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 186. MEA Long Acting Drug Delivery, by Country USD Million (2021-2026)
  • Table 187. MEA Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 188. MEA Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 189. MEA Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 190. Middle East Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 191. Middle East Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 192. Middle East Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 193. Africa Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 194. Africa Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 195. Africa Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 196. North America Long Acting Drug Delivery, by Country USD Million (2021-2026)
  • Table 197. North America Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 198. North America Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 199. North America Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 200. United States Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 201. United States Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 202. United States Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 203. Canada Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 204. Canada Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 205. Canada Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 206. Mexico Long Acting Drug Delivery, by Injectable USD Million (2021-2026)
  • Table 207. Mexico Long Acting Drug Delivery, by End-Use Industries USD Million (2021-2026)
  • Table 208. Mexico Long Acting Drug Delivery, by Implants USD Million (2021-2026)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Long Acting Drug Delivery: by Injectable USD Million (2015-2020)
  • Figure 5. Global Long Acting Drug Delivery: by Implants USD Million (2015-2020)
  • Figure 6. South America Long Acting Drug Delivery Share (%), by Country
  • Figure 7. Asia Pacific Long Acting Drug Delivery Share (%), by Country
  • Figure 8. Europe Long Acting Drug Delivery Share (%), by Country
  • Figure 9. MEA Long Acting Drug Delivery Share (%), by Country
  • Figure 10. North America Long Acting Drug Delivery Share (%), by Country
  • Figure 11. Global Long Acting Drug Delivery share by Players 2020 (%)
  • Figure 12. Global Long Acting Drug Delivery share by Players (Top 3) 2020(%)
  • Figure 13. Global Long Acting Drug Delivery share by Players (Top 5) 2020(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. National Center for Biotechnology Information (United States) Revenue, Net Income and Gross profit
  • Figure 16. National Center for Biotechnology Information (United States) Revenue: by Geography 2020
  • Figure 17. Lubrizol Life Science Health - CDMO Division (United States) Revenue, Net Income and Gross profit
  • Figure 18. Lubrizol Life Science Health - CDMO Division (United States) Revenue: by Geography 2020
  • Figure 19. West Pharmaceutical Services (United States) Revenue, Net Income and Gross profit
  • Figure 20. West Pharmaceutical Services (United States) Revenue: by Geography 2020
  • Figure 21. Celanese (United States) Revenue, Net Income and Gross profit
  • Figure 22. Celanese (United States) Revenue: by Geography 2020
  • Figure 23. DelsiTech Oy (Finland) Revenue, Net Income and Gross profit
  • Figure 24. DelsiTech Oy (Finland) Revenue: by Geography 2020
  • Figure 25. Gerresheimer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Gerresheimer AG (Germany) Revenue: by Geography 2020
  • Figure 27. Baxter International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Baxter International, Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Alkermes Plc. (Irland) Revenue, Net Income and Gross profit
  • Figure 32. Alkermes Plc. (Irland) Revenue: by Geography 2020
  • Figure 33. Becton Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Becton Dickinson and Company (United States) Revenue: by Geography 2020
  • Figure 35. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 37. Schott AG (Germany) Revenue, Net Income and Gross profit
  • Figure 38. Schott AG (Germany) Revenue: by Geography 2020
  • Figure 39. Terumo Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 40. Terumo Corporation (Japan) Revenue: by Geography 2020
  • Figure 41. Unilife Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 42. Unilife Corporation (United States) Revenue: by Geography 2020
  • Figure 43. Endocyte (United States) Revenue, Net Income and Gross profit
  • Figure 44. Endocyte (United States) Revenue: by Geography 2020
  • Figure 45. Genentech Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Genentech Inc. (United States) Revenue: by Geography 2020
  • Figure 47. Global Long Acting Drug Delivery: by Injectable USD Million (2021-2026)
  • Figure 48. Global Long Acting Drug Delivery: by Implants USD Million (2021-2026)
  • Figure 49. South America Long Acting Drug Delivery Share (%), by Country
  • Figure 50. Asia Pacific Long Acting Drug Delivery Share (%), by Country
  • Figure 51. Europe Long Acting Drug Delivery Share (%), by Country
  • Figure 52. MEA Long Acting Drug Delivery Share (%), by Country
  • Figure 53. North America Long Acting Drug Delivery Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • National Center for Biotechnology Information (United States)
  • Lubrizol Life Science Health - CDMO Division (United States)
  • West Pharmaceutical Services (United States)
  • Celanese (United States)
  • DelsiTech Oy (Finland)
  • Gerresheimer AG (Germany)
  • Baxter International, Inc. (United States)
  • Pfizer, Inc. (United States)
  • Alkermes Plc. (Irland)
  • Becton Dickinson and Company (United States)
  • Eli Lilly and Company (United States)
  • Schott AG (Germany)
  • Terumo Corporation (Japan)
  • Unilife Corporation (United States)
  • Endocyte (United States)
  • Genentech Inc. (United States)
Additional players considered in the study are as follows:
Elcam Medical (Italy) , Teva Pharmaceuticals Industries Ltd. (Israel)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation